Studi menemukan, Obat osteoporosis umum berhubungan dengan penurunan risiko kanker payudara --T-REC-komunitas reptil-semaranng--KSE-komunitas satwa eksotik

07.07

payudara

SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE 
DISAMPING KANAN INI............. 

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

................. 

T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA

 

More info :

www.trecsemarang2011.blogspot.com

minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )

08995557626

..................................

KSE – KOMUNITAS SATWA EKSOTIK – EXOTIC PETS COMMUNITY-- INDONESIA

Visit Our Community and Joint W/ Us....Welcome All Over The World

www.facebook.com/groups/komunitassatwaeksotik/

 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA 

DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com 

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )

HUBUNGI   :  089617123865

.........................

Studi menemukan, Obat osteoporosis umum berhubungan dengan penurunan risiko kanker payudara 

Wanita dengan  beberapa jenis obat bone-building  yang digunakan untuk mencegah dan mengobati osteoporosis mungkin berisiko lebih rendah terkena kanker payudara , menurut sebuah studi baru ....read more

Common
osteoporosis drugs are associated with a decrease in risk of breast cancer,
study finds

Date:

March 3, 2010

Source:

Fred Hutchinson Cancer
Research Center

Summary:

Women who take some
types of bone-building drugs used to prevent and treat osteoporosis may be at
lower risk of breast cancer, according to a new study.

.......................

women who take some
types of bone-building drugs used to prevent and treat osteoporosis may be at
lower risk of breast cancer, according to a study by U.S. researchers published
in the British Journal of Cancer.

The study found that women who used bisphosphonate drugs, such as Fosamax,
Boniva and Zomita, for more than two years had a nearly 40 percent reduction in
risk as compared to those who did not, according to lead author Polly Newcomb,
Ph.D., M.P.H., head of the Cancer Prevention Program at Fred Hutchinson Cancer
Research Center.

"This large study provides new evidence that the use of
bisphosphonates is associated with a potentially important reduction in breast
cancer risk," Newcomb said.

The protective effect was observed only among women who were not obese.
"Obese women may have elevated estrogen levels, so underlying hormones may
influence the ability of bisphosphonates to reduce breast cancer risk,"
Newcomb said.

The way in which these drugs may prevent breast cancer is not known, but
several research observations may be relevant. "These drugs may affect
cell function and be important in cell growth and death -- specifically the
death of tumors or even premalignant disease," Newcomb said. Researchers
have found that some kinds of bisphosphonates directly cause tumor apoptosis
(cellular suicide), inhibit angiogenesis (prevent tumors from establishing a
blood supply) and prevent tumor-cell adhesion (the ability of cancer cells to
bind to one another).

The study involved nearly 6,000 Wisconsin women, aged 20 to 69. Half had
been diagnosed with invasive breast cancer and, for comparison purposes, half
had not. The women were interviewed about their bone health -- their history of
fractures, whether they'd been diagnosed with osteoporosis and their history of
bisphosphonate use.

Breast cancer risk factors such as first-degree family history of the
disease, age at first birth, postmenopausal hormone use and body mass index
were accounted for in the analysis. "Because we were able to account for
important cofounders, these findings may reflect real benefits due to the
anti-tumor mechanisms of these medications," the authors wrote.

The National Cancer Institute funded the study, which was conducted in
collaboration with researchers at the University of Wisconsin Carbone
Comprehensive Cancer Center.







Story Source:

The above story is based on materials provided by Fred Hutchinson Cancer Research
Center. Note: Materials may be edited for content and length.




http://www.sciencedaily.com/releases/2010/03/100302195924.htm

READ MORE

Obat keropos tulang dapat membantu mencegah kanker endometrium--T-REC-komunitas reptil-semarang--KSE-komunitas satwa eksotik

09.40

osteoporosis

SILAHKAN MENGGUNAKAN " MESIN TRANSLATE "..GOOGLE TRANSLATE 
DISAMPING KANAN INI............. 

PLEASE USE ........ "TRANSLATE MACHINE" .. GOOGLE TRANSLATE BESIDE RIGHT THIS

................. 

T-REC -TUGUMUDA REPTILES COMMUNITY-INDONESIA

 

More info :

www.trecsemarang2011.blogspot.com

minat gabung : ( menerima keanggotaan seluruh kota dan daerah di Indonesia )

08995557626

..................................

KSE – KOMUNITAS SATWA EKSOTIK – EXOTIC PETS COMMUNITY-- INDONESIA

Visit Our Community and Joint W/ Us....Welcome All Over The World

www.facebook.com/groups/komunitassatwaeksotik/

 KSE = KOMUNITAS SATWA EKSOTIK

MENGATASI KENDALA MINAT DAN JARAK

KAMI ADA DI TIAP KOTA DI INDONESIA 

DETAIL TENTANG KSE-----KLIK : www.komunitassatwaeksotik-pendaftaran.blogspot.com 

GABUNG......... ( menerima keanggotaan seluruh kota dan daerah di Indonesia )

HUBUNGI   :  089617123865

......................... 

Obat keropos tulang dapat membantu mencegah kanker endometrium

Wanita yang menggunakan bifosfonat - obat yang biasa digunakan untuk mengobati osteoporosis dan kondisi tulang lainnya - memiliki hanya sekitar setengah dari risiko terkena kanker endometrium dengan perempuan yang tidak menggunakan obat-obatan, ini  menunjukkan analisis baru.....read more

...........................

Bone loss drugs may help prevent endometrial cancer

Date:

December 22, 2014

Source:

Wiley

Summary:

Women who use bisphosphonates -- medications commonly used to treat osteoporosis and other bone conditions -- have about half the risk of developing endometrial cancer as women who do not use the drugs, a new analysis shows.

.....................

A new analysis suggests that women who use bisphosphonates--medications commonly used to treat osteoporosis and other bone conditions--have about half the risk of developing endometrial cancer as women who do not use the drugs. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study supports other research that has shown an anti-cancer effect of this type of medication.

Endometrial cancer, which arises in the lining of the uterus, accounts for nearly 50 percent of gynecologic cancers diagnosed in the United States, and it is the fourth most common malignancy in women and the eighth most common cause of cancer death. While bisphosphonates are known to prevent bone loss, preclinical studies have shown that the medications also have antitumor effects, including the ability to keep tumor cells from multiplying and from invading normal tissues.

To assess whether bisphosphonates might help prevent endometrial cancer, Sharon Hensley Alford, PhD, of the Henry Ford Health System in Detroit, led a team that evaluated information from the National Cancer Institute's PLCO (Prostate, Lung, Colorectal, and Ovarian) Screening Trial, which included questionnaires about bone medication use. The researchers analyzed data for only those bisphosphonates that contain nitrogen as these are known to have stronger anticancer activity.

A total of 29,254 women were included in the analysis. After accounting for factors including age, race, history of hormone therapy use, smoking status, and body mass index, bisphosphonate users were half as likely to develop endometrial cancer.

"Other studies have shown that bisphosphonates may reduce the risk of certain cancers, but we are the first to show that the risk for endometrial cancer may also be reduced," said Dr. Alford. "This study suggests that women who need bone strengthening medications and who have increased risk for endometrial cancer may want to choose the nitrogen form of bisphosphonates because this form may reduce the risk of endometrial cancer."

---

Story Source:

The above story is based on materials provided by Wiley. Note: Materials may be edited for content and length.

---

Journal Reference:

1.    Sharon Hensley Alford, Ramandeep Rattan, Thomas Buekers, and Adnan Munkarah. Protective effect of bisphosphonates on endometrial cancer incidence in the PLCO data. CANCER, December 2014 DOI:10.1002/cncr.28952

http://www.sciencedaily.com/releases/2014/12/141222083953.htm

READ MORE